Ajay Bansal has left Complete Genomics to join cancer specialists Onconova Therapeutics as chief financial officer and president
Bansal (pictured) served as chief financial officer at Complete Genomics since May 2010, having previously held the role of chief financial officer and executive VP of business development at Lexicon Therapeutics.
He joins US-based Onconova as the company prepares to complete enrolment for a phase III study to investigate lead drug candidate rigosertib in patients with myelodysplastic syndromes.
“The potential benefit of rigosertib for the treatment of patients with both solid and haematological malignancies presents a significant opportunity, and I look forward to helping the company meet its objectives for this compound and the rest of the pipeline,” said Bansal.
In addition to his prior roles at Complete Genomics and Lexicon, Bansal has also served as chief financial officer at Nektar Therapuetics and Tercica, later acquired by Ipsen.